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ABSTRACT
Background. We have previously described a transcriptomic
classiﬁer consisting of metzincins and related genes (MARGS)
discriminating kidneys and other organs with or without ﬁbrosis
from human biopsies. We now apply our MARGS-based algo-
rithm to a rat model of age-associated interstitial renal ﬁbrosis.
Methods. Untreated Fisher 344 rats (n = 76) were sacriﬁced
between 2 to 104 weeks of age. For gene expression studies, we
used single colour (Cy3) Agilent Whole Rat Genome 4 × 44k
microarrays; 4–5 animals of each sex were proﬁled at each of the
following ages: 2, 5, 6, 8, 15, 21, 78 and 104 weeks. Intensity
data were subjected to variance stabilization (www.Partek.com).
Data were analysed with ANOVA and other statistical methods.
Results. Sixty MARGS were differentially expressed across age
groups. More MARGS were differentially expressed in older
males than in older females. Principal component analysis
showed gene expression induced segregation of age groups by
sex from 6 to 104 weeks of age. The expression level of MMP7
correlated best with ﬁbrosis grade. Severity of ﬁbrosis was deter-
mined in 20 animals at 78 and 104 weeks of age. Expression
values of 15 of 19 genes of the original classiﬁer present on the
Agilent array, in conjunction with linear discriminant analysis,
was sufﬁcient to correctly classify these 20 samples into
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non-ﬁbrosis and ﬁbrosis. Overrepresentation of MMP2 protein
and CD44 protein in ﬁbrosis was conﬁrmed by immunoﬂuores-
cence.
Conclusions. Based on these results and our previous work,
the MARGS classiﬁer represents a cross-organ and cross-
species classiﬁer of ﬁbrosis irrespective of aetiology. This
ﬁnding provides evidence for a common pathway leading to
ﬁbrosis and will help to design a PCR-based clinical test.
Keywords: ageing, CD44, classiﬁer, ﬁbrosis, matrix metallo-
proteinases, metzincins
INTRODUCTION
Ageing is a programmed biological process involving alter-
ation of transcription of genes associated with many cell sig-
nalling pathways including cell survival, cell proliferation, cell
transport and energy metabolism [1–3]. Such alterations of
transcription results in cellular or replicative senescence in-
creased susceptibility to apoptosis, decreased functional cap-
acity of stem cells and progenitor cells, altered expression of
growth factors, mitochondrial dysfunction and impaired re-
generation and repair in the ageing kidney. This ageing pheno-
type leads to renal dysfunction, glomerulosclerosis, interstitial
ﬁbrosis and arteriosclerosis [4].
Fibrosis and sclerosis are the outcome of progressive
chronic kidney diseases, which ultimately lead to end-stage
renal disease (ESRD) requiring maintenance dialysis or kidney
transplantation [5, 6]. Identiﬁcation of molecular markers for
renal ﬁbrosis is of paramount clinical importance to reﬁne
current diagnosis and treatment by identiﬁcation of novel
therapeutic targets.
Tubulointerstitial ﬁbrosis is characterized by proliferation
and transformation of ﬁbroblasts into myoﬁbroblasts, depos-
ition of ﬁbronectin and collagens I and III into the intersti-
tium, inﬂammation, microvascular rarefaction, podocyte
depletion and deposition of extracellular matrix (ECM) in the
interstitial space between nephrons [5]. These pathophysio-
logical characteristics occur coincidently with the synthesis
and secretion of inﬂammatory mediators, including inter-
feron-γ, tumour necrosis factor-α, interleukin-1β and trans-
forming growth factor-β (TGF-β), and members of the
metzincins and related genes (MARGS) [6–8]. Within the
group of MARGS, matrix metalloproteinases (MMP) are in-
volved beyond their role as ECM-degrading enzymes in many
physiological and pathological processes [9]. Examples of
normal conditions are embryonic development, ovulation and
wound healing [9, 10]. Important pathologic conditions with
MMP involvement are inﬂammatory bowel diseases, arthritis,
aortic aneurysms and chronic obstructive pulmonary disease
[9, 11, 12]. In addition, MARGS including the TGFβ pathway
and MMP play an important role in ﬁbrosis development of
solid organs and they have already been successfully used as
therapeutic targets in this respect [13].
Previously we have identiﬁed a high-sensitivity, high-
speciﬁcity transcriptomic classiﬁer consisting of 19 MARGS
that could discriminate human renal allograft biopsies with or
without interstitial ﬁbrosis/tubular atrophy (IF/TA) [14].
Subsequently, these classiﬁer analyses were extended to non-
transplant solid organs, such as heart, lungs, liver, kidneys and
pancreas, affected with and without ﬁbrosis [15].
The data herein are a sub-study of a larger comprehensive
time-course experiment of male and female Fisher 344 rats,
comprising eight age groups from 2 weeks to 104 weeks of age
[2, 3, 16].
In this study, we examined age-induced alteration of renal
expression of the MARGS genes, and investigated whether the
previously described MARGS-based ﬁbrosis classiﬁer has
diagnostic value across species in an experimental rat model of
age-associated interstitial ﬁbrosis.
SUBJECTS AND METHODS
Animal study
The rat in-life study, sample processing and microarray
analysis were described earlier in detail [2, 3, 16]. Brieﬂy,
kidneys were obtained from the following number of Fisher
344 rats: n = 4 for 2, 5, 6, 8 and 104-week males; n = 5 for 15,
21 and 78-week males and 2, 5, 6, 8, 15, 21, 78 and 104-week
females (Supplementary Table S1). These male and female
(unsynchronized) Fisher 344 rats obtained from the animal
breeding colony of the National Centre for Toxicological Re-
search (NCTR) were fed the NIH-31 diet and housed under
AAALAC-approved conditions with a 12-h light/dark cycle
(0600–1800). Rats were treated according to the NCTR Insti-
tutional Animal Care and Use Committee guidelines (USA).
Necropsy
Animals were sacriﬁced at the same circadian time
(between 0900 and 1100) for each time point and euthanized
by carbon dioxide asphyxiation. Body weights were recorded,
and kidney tissues were ﬂash frozen in liquid nitrogen and
stored at −80°C. Kidneys were collected at 52, 78 and 104
weeks of age for histological examination and placed in 10%
neutral buffered formalin. Kidneys from other ages were not
examined because historical data from the animal colony sug-
gested that no ﬁbrosis would be present.
RNA isolation
Total RNAwas isolated from ∼30 mg of ground kidney using
Qiagen RNeasy Mini Kit (Qiagen, Inc., Valencia, CA, USA) ac-
cording to manufacturer’s protocol. The yield of the extracted
RNA was determined by Nanodrop-1000 (Thermo Scientiﬁc,
Wilmington, DE, USA). Purity and quality of RNA were evalu-
ated using the RNA 6000 LabChip and Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA). RNA samples with
RNA integrity numbers >8.0 (average of 8.7) were used.
Microarray experiments
Single colour (Cy3) Agilent Whole Rat Genome 4 × 44k
microarrays were used for measurement of relative mRNA
levels [3]. Full microarray data are available at Gene Expression
Omnibus with accession GSE47070 (http: //www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE47070).
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Microarray data analysis
Intensity ﬁles were subjected to variance stabilization in-
cluding log2 transformation (www.Partek.com). Expression
measures of multiple probes corresponding to a single Entrez
gene were summarized as the mean value for those measures.
After initial visual inspection of the data, three samples were
excluded from further analysis due to suspected outlier behav-
iour of unknown source: Week 5 female 1, Week 15 male 5
and Week 21 male 6. One hundred and sixty-three MARGS
genes are represented on the Agilent Rat Whole Genome
4 × 44k array (Supplementary Table S2). Data were analysed
with ANOVA using sex and/or age as factors. Differential ex-
pression was deﬁned as P-value ≤0.05 and |fold change| ≥1.5.
Correlation of gene expression signal intensities to ﬁbrosis
grade was calculated as the Pearson correlation r (www.Partek.
com).
Gene set enrichment analysis (GSEA) was performed as de-
scribed earlier [17], and is available from www.broadinstitute.
org/gsea/. Except for the MARGS list, which was assembled by
the authors, gene sets were obtained from SABiosciences
(www.SABiosciences.com) and are listed in Supplementary
Table S2.
Pathology of rat kidney
Haematoxylin- and eosin-stained slides were evaluated for
ﬁbrosis. In all cases, the left kidney was analysed. Fibrosis was
deﬁned as an abnormal accumulation of ECM that replaces or
expands/thickens normal kidney structures. The severity score
of the ﬁbrosis was based upon a grading criteria of 0–4: 0 = no
increase in the amount of collagen; 1≤ 5%; 2≤ 5–35%;
3 = 36–65%; 4≥ 65% of the renal cortex containing an in-
creased amount of ECM interpreted as collagen. This semi-
quantitative scoring was performed by a single pathologist in a
blinded fashion [3].
Immunoﬂuorescence
Sections (5 μm) of formalin-ﬁxed and parafﬁn-embedded
kidney samples were used. Immunostainings for CD44 and
MMP2 were performed as previously described [18, 19].
Brieﬂy, CD44 was detected by incubating the kidney sections
with mouse monoclonal anti-rat-CD44 (OX-49) antibody
(554869, BD Pharmingen, San Diego, CA, USA) diluted
1:50, followed by incubation with anti-mouse secondary anti-
body conjugated with GFP (F2883, Sigma-Aldrich, Buchs,
Switzerland, 1:100 dilution in 1× TBS).
To detect MMP2, kidney sections were incubated with goat
polyclonal anti-human-MMP2 (C19) antibody (sc-6838,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) diluted
1:50. Thereafter, kidney sections were incubated with anti-
rabbit secondary antibody conjugated with TRITC (T6778,
Sigma-Aldrich, Buchs, Switzerland) in a dilution of 1:100.
DAPI was utilized for nuclear staining (H-500, Vector Labora-
tories, Irvine, CA, USA). Fluorescence imaging was recorded
in an Axiovert 200M microscope with a laser scanning module
LSM 510 META (Carl Zeiss AG, Feldbach, Switzerland).
DAPI was excited at 405 nm, FITCH at 488 nm and TRITCH
at 588 nm.
RESULTS
Age- and sex-related differences in the expression
of MARGS
Whole genome proﬁling of rat kidney gene expression of
4–5 animals per sex and age group was performed according
to the workﬂow described in [2]. As we were particularly inter-
ested in expression changes of MARGS genes over time and
sex, we examined 163 MARGS, which are represented on the
array type used in this study, the Agilent Whole Rat Genome
4 × 44k array slide (Supplementary Table S2). Unsupervised k-
means clustering was applied to identify patterns of expression
across age groups (Figure 1A). The cluster analysis was per-
formed with all age groups and sexes (16 analysis groups). Ten
such clusters were chosen, as more clusters would have led to a
pattern redundancy, and less would have rendered too few
gene groups. Some exemplary expression proﬁles are shown in
Figure 1B. The expression of many collagen genes decreases
with age until Week 78, but slightly increases again until Week
104, particularly in male animals (clusters 1 and 2, Figure 1A),
while the expression patterns of ADAMs (transmembrane
proteins belonging to the zinc protease superfamily) are quite
heterogeneous (compare, for example, Figure 1A, panel 3 and
10). The results of the cluster analysis by gene are provided in
Supplementary Table S3.
Sex differences in age-related changes of MARGS
expression
To analyse the temporal expression proﬁle of MARGS and
potential sex differences, we performed t-tests by sex for each
age group, and ﬁltered out those MARGS with a P-value
≤0.05 and an absolute fold change between age-matched
sex groups of 1.5, which meets the recommendation by The
MicroArray Quality Control Consortium [20]. In addition
these genes had an ANOVA P-value ≤0.05 across all analysis
groups (age and sex). As shown in Figure 2, the number of
sexually dimorphic MARGS genes increases with age. While
differentially expressed MARGS tend to be expressed at higher
levels in females than in males in younger age groups up to
∼21 weeks (with the exception of the Week 2 group), almost
all differentially expressed MARGS are expressed at higher
levels in males at 78 weeks and 104 weeks of age. Across all age
groups 60 MARGS were differentially expressed, some of them
in more than one age group.
Next we applied principal component analysis (PCA),
which is a dimension reduction factor analysis method, to esti-
mate and visualize variance in the dataset. As shown in
Figure 3, the explained variance of the ﬁrst two principal com-
ponents (PCs) increases from 32.9% when using all unique
Entrez IDs on the array (Figure 3A and B) to 43.7% when
using all MARGS (Figure 3C and D). As can be seen in
Figure 3C and D, MARGS expressions lead to a trend of segre-
gation by age groups, where male and female groups follow a
very similar pattern up to Week 21 and then split. Using the
60 MARGS that are differentially expressed between sexes at
any time point maintained the age-dependent pattern seen
with all MARGS (Figure 3E) and increased the explained
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variance of PC1 and PC2 to 60.8%. The segregation of the age
groups by sex becomes prominent by 6 weeks of age
(Figure 3F), which may reﬂect sex-speciﬁc gene expression
changes of MARGS after 6 weeks of age. The largest variance
in the dataset comes from the factor age and is explained by
PC1. PC2 appears to explain additional differences within
the older age groups of Week 78 and 104. One may speculate
that there is some difference in age-related factors, e.g. differ-
ent grades of ﬁbrosis. PC3 appears to explain differences in
sex.
MARGS expression in age-induced kidney ﬁbrosis
As MARGS play a role in ﬁbrosis, we next addressed the
question whether there is a detectable relationship between
MARGS gene expression and age-associated ﬁbrosis. Patho-
logical examinations of 20 kidneys revealed that severity of
ﬁbrosis was greater in male rats than in female rats and also se-
verity of ﬁbrosis increased with age (Supplementary Table S1).
Four of the examined kidneys in the present study had no ﬁ-
brosis (age: Week 78), 16 were positive for ﬁbrosis (age: Week
78 and 104). Prior to Week 78, only a minority of the investi-
gated samples displayed ﬁbrosis grade 1 at Week 52, whereas
most samples were without ﬁbrosis at that time point (Supple-
mentary data Table S1). Samples fromWeek 52 were not avail-
able for microarray analysis.
To investigate whether MARGS were signiﬁcantly changed
in 16 samples with presence of ﬁbrosis in comparison to
four non-ﬁbrotic tissue specimens, we followed two analysis
methods, a gene-centric and a pathway/network-centric ap-
proach. For the gene-centric approach, MARGS genes that
were differentially expressed (P-value ≤0.05, fold change ≥1.5)
between non-ﬁbrotic and ﬁbrotic samples, regardless of age,
were identiﬁed. The 27 differentially expressed MARGS are
shown in Figure 4A. All of them were overrepresented in
samples with ﬁbrosis. MMP7 was overexpressed by >8-fold in
ﬁbrotic kidneys, and 10 others, including CD70 and MMP25,
were overexpressed by at least 2-fold. Overrepresentation of
CD44 and MMP2 proteins in ﬁbrosis was conﬁrmed by im-
munoﬂuorescence, as demonstrated in Figure 4B. Eleven of 15
collagens in the MARGS list are overexpressed in ﬁbrosis, al-
though not all of them met the ﬁltering criteria for differential
expression (data not shown). mRNA expression levels of
MMP7 had the highest correlation to ﬁbrosis grade, followed
by TNFRSF9 and SERPINE1, as shown in Figure 4C.
F IGURE 1 : Self-organizing map clustering of MARGS genes across
eight age groups and two sexes. (A) Clusters of co-expressed genes.
X-axis labels for Week 5, 8, 21 and 104 were omitted due to space
limitation. The normalized expression values and the assignment of
MARGS genes to the clusters are provided in Supplementary
Table S2. (B) Exemplary genes and their clusters as shown in (A):
CD44 (cluster 8); MMP2 (cluster 2); COL3A1 (cluster 1); MMP7
(cluster 8), SPP1 (cluster 8); TGFb1 (cluster 6). In both (A) and (B),
mean age group expression values were standardized to a mean of
zero and scaled to a standard deviation of 1.
F IGURE 2 : Temporal proﬁle of sex differences in kidney expression
of MARGS genes. The number of genes exhibiting a minimum
1.5-fold difference in expression between male and female animals
and maximum P-value of 0.05 was calculated at each age group.
In addition, these genes had an ANOVA P-value ≤0.05 across all ana-
lysis groups (age and sex). These data illustrate that the number of
sexually dimorphic MARGS increases with age. Also, these sexually
dimorphic MARGS are generally expressed at a higher level in males
than females at older age (78 and 104 weeks).
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A pathway- and gene-network-centric approach was
applied to determine if the group of MARGS genes and other
gene groups with MARGS are differentially affected during
ageing. In addition to the gene set of MARGS, gene sets epi-
thelial–mesenchymal transition (EMT), ECM, the TGF beta
pathway and immune response genes were focused on (Sup-
plementary Table S2). These were subjected to a GSEA across
predeﬁned age groups, ‘young’ (2 and 5 weeks old), ‘adult’ (15
and 21 weeks old) and ‘old’ (78 and 104 weeks old). As shown
in Figure 5, MARGS are signiﬁcantly overrepresented in
young compared with old, young compared with adult and in
old compared with adult. A similar trend was observed with
the genes involved in EMT, ECM, TGF-β pathway and ﬁbrosis.
In contrast, immune response genes are overrepresented in old
versus young, and adult versus young, and overrepresented in
old when compared with adult (Figure 5).
The MARGS-based classiﬁer of ﬁbrosis
We next tested whether MARGS genes could serve as a sur-
rogate marker for ﬁbrosis in ageing rat kidneys. We previously
F IGURE 3 : Effect of gene selection on data structure. PCAwith all 17 362 unique Entrez genes represented on the array type (A and B), with
all MARGS (n = 163) (C andD), and with differentially expressed MARGS (n = 60) (E and F). (A, C and E) Each symbol represents a rat sample.
(B, D and F) Each data point represents the centroid of the age group corresponding to the plots on the left. The centroids of each age group are
connected by sex. In each panel, a sphere represents female, a tetrahedron represents male.
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F IGURE 4 : Differential expression of MARGS genes in ﬁbrosis. (A) ANOVA analysis of ﬁbrosis versus non-ﬁbrotic samples. Twenty-seven
MARGS had a P-value ≤0.05 and an absolute fold change ≥1.5. Genes were ranked by the smallest P-value and largest absolute fold change (A,
left). Box plot of the three MARGS with largest absolute fold change (A, right). (B) Exemplary staining images of kidney ﬁbrosis in present
dataset. Left, haematoxylin stainings of control (ﬁbrosis score = 0) = ‘C’, and ﬁbrosis (score = 3) = ‘F’. Centre, CD44 is overexpressed in proximal
(shown) and distal convoluted tubules, glomeruli and blood vessels in renal cortex of ageing rats. Right, MMP2 is overexpressed in the cortical
interstitium. Magniﬁcation: MMP2: ×63, CD44: ×40; MMP2: ×63. (C) MARGS with correlation r > 0.65 to ﬁbrosis in 20 samples with ﬁbrosis
scores. Box plots of three MARGS with largest correlation to ﬁbrosis scores are shown in (C), right.
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published that expression levels of a panel of MARGS genes in
combination with the decision algorithm linear discriminant
analysis (LDA) can serve as a classiﬁer of ﬁbrosis in renal
tissue in humans [15]. The same classiﬁer was applied to
samples in the present study. Of 19 MARGS genes of the ori-
ginal classiﬁer which was developed based on human Affyme-
trix HG-U133 v2 arrays, 15 genes were represented on the rat
Agilent array: ADAM28, ADAMTS5, ADAMTSL3, CD44,
COL3A1, EMILIN2, LAMB1, MGP, PAPLN, PLG, THBS1,
THBS2, THSD1, TNFSF10 and VEGFA. Despite this limita-
tion, all samples were classiﬁed correctly, the AUC was 1.0 and
the accuracy was therefore 100%, as given in Table 1.
Previously, we also tested a composite transcriptomics
classiﬁer, which consisted of 10 of the 19 MARGS of the
original ﬁbrosis classiﬁer [15]. This subset had been generated
as a result of data integration from different array platforms
taken from the literature. Ten MARGS were present on all
platforms: CD44, THBS2, VEGFA, PLG, TNFAIP3, LAMB1,
TNFSF10, COL3A1, THBS1 and MGP. In the present rat
Agilent array, only TNFAIP3 was not represented among
these 10 genes. Despite this limitation, the composite nine
MARGS classiﬁer performance in the rat ageing kidney
dataset reached a signiﬁcant AUC of 1 and therefore an accur-
acy of 100% (Table 1).
Taken together, the MARGS classiﬁer, or a subset of it—in
conjunction with the decision algorithm LDA—was sufﬁcient
to correctly classify all 20 samples with histopathology results
into non-ﬁbrosis (n = 4) and ﬁbrosis (n = 16).
F IGURE 5 : Gene set enrichment analysis (GSEA) for six gene sets with MARGS involvement. GSEAwas performed with samples from 2- and
5-week-old rats (‘young’), 15- and 21-week-old rats (‘adult’) and from 78- and 104-week-old rats (‘old’). Normalized enrichment score (NES) is
deﬁned as the enrichment score divided by the mean of the enrichment scores against all permutations of the dataset. Nominal P-value is the
statistical signiﬁcance of an enrichment score for a given gene set. The false discovery rate (FDR) provides an estimate of the NES being a false-
positive ﬁnding. The number of genes in the gene set is given under ‘size’. Gene sets are provided in Supplementary Table S1. P-values and FDR
<0.05 are labelled in red. The graphs on the right are scatter plots of the mean signal intensities of compared groups. Each dot represents a single
gene of the gene set. Dark blue dots represent enriched genes; grey dots are non-enriched genes of the gene set.
Table 1. Performance of classiﬁers
Classiﬁer panel Fibrosis
samples
Control
samples
Correct classiﬁcation
rate (%)
Sensitivity
(%)
Speciﬁcity
(%)
ACC AUC
15 MARGS genes on array 16 4 100 100 100 1 1
9 of 10 MARGS genes on array from ‘minimal
classiﬁer’
16 4 100 100 100 1 1
ACC, accuracy; MCC, Matthews correlation coefﬁcient; AUC, Area under ROC curve.
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DISCUSSION
Prevalence of ESRD requiring chronic dialysis or renal trans-
plantation continues to increase [21]. ESRD is characterized
by progressive ﬁbrosis leading to sclerosis, irrespective of its
primary aetiology [22]. Accordingly, the extent of tubulointer-
stitial ﬁbrosis was found to be the best predictor for kidney
survival, irrespective of the underlying disease [22]. The
annual cost of 1 year of dialysis treatment is >100 000 US
dollars per patient in most countries. Considerable morbidity
and mortality are associated with dialysis and transplantation
[23, 24]. Fibrosis is difﬁcult to treat and irreversible in the
more advanced states. Thus, immunosuppressive therapy di-
rected at underlying diseases like glomerulonephritis or vascu-
litis is often without beneﬁt with respect to reversal of ﬁbrosis.
In addition, prolonged immunosuppression has severe side
effects. Therefore, novel diagnostic and therapeutic strategies
based on new biomarkers are necessary. To date, there are no
validated transcriptomic biomarkers in routine clinical use
for diagnosis of kidney ﬁbrosis, treatment guidance or drug
targets. Timely diagnosis with reﬁned treatment indication
based on biomarkers and novel therapeutic targets will greatly
improve care of patients suffering from these two difﬁcult to
treat conditions. In addition, better patient care and preven-
tion of kidney ﬁbrosis will have implications beyond ageing for
many frequent and highly relevant chronic renal diseases, such
as diabetic nephropathy and hypertensive nephrosclerosis.
Recently, several novel potential ﬁbrosis biomarkers have
been identiﬁed. The miR-21 was found to be a potential novel,
predictive and reliable blood marker of kidney ﬁbrosis [25]. In
another study, expression of TNFRSF6B in kidney tissues was
found to be associated with renal ﬁbrosis and to represent a
biomarker for predicting the progression of chronic kidney
disease [26]. In a genetic mouse model, gene expression proﬁl-
ing followed by biological validation identiﬁed HE4 (encoding
human epididymis protein 4) as the most up-regulated gene in
ﬁbrosis-associated myoﬁbroblasts. In that study, HE4 inhibited
activity of serine proteases as well as MMP, and their capacity
to degrade type I collagen. Thus, HE4, which is also elevated
in serum of patients with kidney ﬁbrosis, represents a potential
biomarker of kidney ﬁbrosis and a new drug target [27].
Especially in the Western world, the ageing population
with chronic kidney diseases add to the burden of health care
[28]. Thus, the investigation of age-related problems is of
paramount importance in clinical practice. The ageing
kidney is characterized by an augmented number of sclerotic
glomeruli and interstitial ﬁbrosis [21]. Accordingly, in our
animal study, the degree of ﬁbrosis increased with age. We
have recently shown an overrepresentation of MMP2,
MMP7, COL3A1, TIMP, SPP1 and other genes in ﬁbrotic
specimens of various human tissues of various aetiologies
[15]. Those genes are also overrepresented in age-induced rat
samples in the present study, implying that they are generally
involved in ﬁbrosis, regardless of the aetiologies and species.
In addition, CD44, another member of the proposed ﬁbrosis
classiﬁer, is differentially expressed between ﬁbrotic and non-
ﬁbrotic samples. The expression of MMP7 and CD44, which
binds a hyaluronic acid, a component of the ECM, and func-
tions as lymphocyte homing factor and cell migration mediator
[29], increases with age in both female and male rats. Others
such as MMP2 and COL3A1 exhibit relatively high expression
in very young renal specimens; then the expression decreases
towards the adult stage and increases again towards to old age.
This expression proﬁle may be indicative of highly relevant pro-
cesses of ECM remodelling during very early phases of growth,
which is then alleviated during adulthood, but required again
during senescence. The proteases MMP2 and MMP9 contribute
to the activation of the pro-ﬁbrogenic cytokine TGFb1 [7],
whose expression also increases towards old age (Figure 1B).
Previously, we have shown that MMP7 is overexpressed early in
the course of interstitial ﬁbrosis and tubular atrophy [14].
Overall, MMP7, CD70 and MMP25 are the MARGS with the
highest fold-change increase in ﬁbrosis. Not only is MMP7 the
MARGS gene with the highest absolute fold change between ﬁ-
brotic and non-ﬁbrotic samples, its expression also correlated
best with ﬁbrosis grade. Thus, MMP7 may represent a biomark-
er for ﬁbrosis.
Especially, the putative role of increased MMP7 in ﬁbrosis
is very much in line with a very recent and related publica-
tion demonstrating a mechanistic link between up-regulated
MMP7 and ﬁbrosis development via MMP7 mediated aug-
mented collagen 1A2 expression [30].
Expression values of a set of genes derived from the original
human ﬁbrosis study [15], in conjunction with LDA, were sufﬁ-
cient to correctly classify a set of rat kidney samples—for which
gene expression data and ﬁbrosis scores were available—into
non-ﬁbrosis and ﬁbrosis. Therefore, we have developed a clas-
siﬁer across species for human and murine ﬁbrosis. Spe-
ciﬁcally, the classiﬁer was developed based on a binominal
distribution of presence and absence of ﬁbrosis in the present
and in previous publications and thus cannot be applied for
different ﬁbrosis grades or scores without further validation
studies using much higher sample sizes.
After further validation in prospective studies and also
based on our previously cited human studies, such a common
classiﬁer may support the putative existence of a similar ﬁnal
pathway of ﬁbrosis irrespective of its aetiology and may be
used for drug testing in animal models and for diagnosis of ﬁ-
brosis, including judgment of prognosis. Such interventional
studies would also be required to demonstrate the exact func-
tional role and consequences of deregulated MARGS includ-
ing MMP in age-related ﬁbrosis development.
In conclusion, this MARGS classiﬁer represents a cross-
organ and cross-species classiﬁer of ﬁbrosis irrespective of
aetiology. This ﬁnding provides evidence for a common
pathway leading to ﬁbrosis and helps to design a PCR-based
clinical test.
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